medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2016, Number 1

Next >>

Neumol Cir Torax 2016; 75 (1)

Methods for estimating health costs of COPD: baseline results

Fernández-Plata R, Martínez-Briseño D, García-Sancho FC, Cano-Jiménez D, Ramírez-Venegas A, Sansores-Martínez R, Torre-Bouscoulet L, Casas-Medina G, Pérez-Padilla R

Language: Spanish
References: 30
Page: 4-11
PDF size: 215.22 Kb.


ABSTRACT

Background: The PLATINO study developed in Mexico City (2003) showed a COPD prevalence of 7.8% in individuals 40 years of age and older. In Mexico, there is no published information concerning direct and indirect health related costs for patients with COPD. Objective: To measure direct and indirect costs of outpatients with COPD at a tertiary-level hospital in Mexico. Material and methods: We recruited outpatients with diagnosis of COPD during one year. At base-line interview we asked about out of pocket health expenses for the last year previous to enrollment. Costs for the hospital were registered as well. For this study, we analyzed costs in 2014 US dollars for the last year previous enrollment in patients with › 12 months of being diagnosed stratified by GOLD categories. Results: We enrolled 611 outpatients with COPD, of whom 483 had a time of diagnosis › 12 months. The medians of annual direct costs to patients by GOLD were: $1,116, mild; $1,533, moderate; $1,825, severe, and $2,245, very severe. The differences among the medias of annual direct cost were statically signified (p ‹ 0.01). Conclusions: Direct out of pocket costs increased with COPD severity and were due to drugs, oxygen, and accommodations mainly. It is important to have a standardized methodology to make the results comparable.


REFERENCES

  1. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD). Fact sheet No 315. Access date: March 17, 2015. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/

  2. Ladeira I, Gomes T, Castro A, Ribeiro C, Guimarães M, Taveira N. The overall impact of COPD (CAT) and BODE index on COPD male patients: correlation? Rev Port Pneumol 2015;21(1):11-15. doi: 10.1016/j.rppnen.2014.02.004.

  3. Aït-Khaled N, Enarson DA, Ottmani S, El Sony A, Eltigani M, Sepulveda R. Chronic airflow limitation in developing countries: burden and priorities. Int J Chron Obstruct Pulmon Dis 2007;2(2):141-150.

  4. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S81-89.

  5. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S71-79.

  6. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S61-69.

  7. Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S51-59.

  8. Piperno D, Huchon G, Pribil C, Boucot I, Similowski T. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S33-42.

  9. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S43-50.

  10. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003;97 Suppl C:S23-31.

  11. Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest 2002;122(6):1994-2002.

  12. Miller JD, Foster T, Boulanger L, et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005;2(3):311-318.

  13. Pérez N, Murillo R, Pinzón C, Hernández G. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS). Rev Colomb Cancerol 2007;11(4):241-249.

  14. Simoni-Wastila L, Blanchette CM, Qian J, et al. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Pharmacother 2009;7(5):262-270. doi: 10.1016/j.amjopharm.2009.11.003.

  15. Sharafkhaneh A, Petersen NJ, Yu HJ, Dalal AA, Johnson ML, Hanania NA. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis 2010;5:125-132.

  16. Dalal AA, Shah M, D’Souza AO, Rane P. Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population. J Med Econ 2010;13(4):591-598. doi: 10.3111/13696998.2010.521734.

  17. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010;5:341-349. doi: 10.2147/COPD.S13771.

  18. Masa JF, Sobradillo V, Villasante C, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol 2004;40(2):72-79.

  19. Strâmbu I, Bucşa S, Nicolescu D, Dumitrescu C, Grigorescu B, Stoicescu IP. Cost analysis in patients admitted with COPD in 2002. Pneumologia 2004;53(4):161-168.

  20. Bakerly ND, Davies C, Dyer M, Dhillon P. Cost analysis of an integrated care model in the management of acute exacerbations of chronic obstructive pulmonary disease. Chron Respir Dis 2009;6(4):201-208. doi: 10.1177/1479972309104279.

  21. Menezes AM, Pérez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366(9500):1875-1881.

  22. Consenso Mexicano de EPOC; Ramírez VA, Sansores MR. Panorama epidemiológico e impacto económico actual. Neumol Cir Torax 2007;66(Supl 2):S13-S16.

  23. Reynales-Shigematsu LM, Rodríguez-Bolaños RA, Jiménez JA, Juárez-Márquez SA, Castro-Ríos A, Hernández-Ávila M. Costos de la atención médica atribuibles al consumo de tabaco en el Instituto Mexicano del Seguro Social. Salud Pública Mex 2006;48(Supl 1):S48-S64.

  24. Reynales-Shigematsu LM, Juárez-Márquez SA, Valdés-Salgado R. Costos en atención médica atribuibles al tabaquismo en el IMSS, Morelos. Salud Pública Mex 2005;47(6):451-457.

  25. Cano-Valle F. Día Mundial de la EPOC. Rev Inst Nal Enf Resp Mex 2006;19(4):247.

  26. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13(1 Pt 1):1-7.

  27. Comisión Nacional de Salarios Mínimos (CONASAMI). Tabla de salaries mínimos por área geográfica. Fecha de consulta: 14 de abril, 2015. Accesible en: http://www.conasami.gob.mx/t_sal_mini_prof.html.

  28. World Bank (WB). GDP per capita (current US$). Access date: April 14, 2015. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.

  29. Organization for Economic Co-operation and Development (OCDE). Income nequality and Poverty. Figures and Data. Access date: April 14, 2015. Available from: http://www.oecd.org/social/inequality-and-poverty.htm.

  30. Herdman M, Badia X, Berra S. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Aten Primaria 2001;28(6):425-429.




2020     |     www.medigraphic.com